Cefdinir Uses: Ear, Sinus, and Skin Infections

Cefdinir is an oral antibiotic used to treat a range of common bacterial infections, including ear infections, strep throat, sinus infections, bronchitis, pneumonia, and skin infections. It belongs to the third-generation cephalosporin class and works against many of the bacteria responsible for everyday community-acquired illnesses. The drug is available in both capsule and liquid suspension forms, making it a frequent choice for both adults and children. But how cefdinir stacks up against other antibiotics, where it genuinely shines, and what quirks you should know about vary quite a bit depending on the infection being treated.

How Cefdinir Works

Cefdinir kills bacteria by interfering with their ability to build cell walls, which is the same basic mechanism behind penicillin and other cephalosporins. What sets it apart is its unusually broad reach. It covers many gram-positive bacteria like Streptococcus pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes, along with gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Those five pathogens are responsible for the vast majority of common respiratory and skin infections treated in outpatient clinics.¹ One practical advantage is that cefdinir resists breakdown by many of the enzymes (called beta-lactamases) that bacteria use to inactivate older antibiotics. That stability helps explain why it remains effective against strains that have developed resistance to simpler drugs like amoxicillin.

Ear Infections in Children

Acute otitis media, the standard middle ear infection, is one of the most common reasons children are prescribed antibiotics, and cefdinir is frequently used here. The evidence supports its role as a solid second-line option when amoxicillin alone isn’t cutting it or when the child has already failed a first course. A five-day course of cefdinir was shown to effectively eradicate common ear-infection pathogens, including strains of S. pneumoniae with intermediate penicillin resistance and beta-lactamase-producing organisms.²

Head-to-head trials have compared cefdinir to other commonly prescribed alternatives. When tested against a ten-day course of cefprozil, a five-day course of cefdinir was just as clinically effective and well tolerated.³ Against ten days of low-dose amoxicillin-clavulanate, five days of cefdinir produced comparable clinical response rates, roughly 88% versus 85%.⁴ The shorter course length is a genuine practical benefit for families. Getting a young child to take medicine reliably for ten days is harder than five, and a shorter course means fewer missed doses.

Strep Throat and Tonsillitis

Strep throat caused by Group A beta-hemolytic streptococcus is the textbook reason for throat antibiotics, and the traditional first-line treatment is a ten-day course of penicillin. Cefdinir outperforms penicillin here by a meaningful margin. In a pooled analysis of clinical trials, cefdinir produced a clinical cure rate of about 94% versus 83% for penicillin, and its bacterial eradication rate was 92% compared with 77% for penicillin.⁵ Those are clinically and statistically significant differences.

A large network meta-analysis comparing 24 different antibiotics across 64 randomized controlled trials reinforced this picture. Cefdinir was about three times more effective than penicillin V at early bacterial eradication and roughly twice as effective for early clinical response.⁶ Despite these numbers, penicillin remains the standard first-line recommendation in most guidelines. The reasoning has to do with cost, narrow spectrum (penicillin targets strep without wiping out as many other bacteria), and the goal of limiting the development of antibiotic resistance. Cefdinir is typically reserved for patients who can’t tolerate penicillin or who fail a first course.

Sinus Infections

Acute bacterial sinusitis is another common use. Most sinus infections start as viral, and antibiotics are only appropriate when symptoms persist beyond about ten days, worsen after initial improvement, or are unusually severe. When an antibiotic is warranted, cefdinir has performed on par with amoxicillin-clavulanate in clinical trials, achieving roughly 90% cure rates whether given once or twice daily.⁷ It also showed efficacy comparable to levofloxacin, a fluoroquinolone, with the benefit of good tissue penetration in the respiratory tract and once-daily dosing.⁸

The once-daily option matters for convenience, though there’s a caveat worth knowing. In an in vitro study modeling how the drug behaves against typical respiratory pathogens, twice-daily dosing was more effective than once-daily dosing at killing bacteria and preventing regrowth over 24 hours.⁹ Your prescriber’s choice of once versus twice daily usually depends on the severity and type of infection. For community-acquired pneumonia specifically, twice-daily dosing is likely the better strategy.

Skin and Soft Tissue Infections

Uncomplicated skin infections like impetigo, wound infections, and minor abscesses round out cefdinir’s approved uses. Here, the drug has been tested extensively against cephalexin, an older and more widely prescribed first-generation cephalosporin. The results are consistently similar. In adults and adolescents with mild to moderate skin infections, both drugs produced clinical cure rates of about 89%.¹⁰ An earlier trial found comparable results, with cefdinir achieving an 88% clinical response rate versus 87% for cephalexin, and cefdinir taken twice daily matched cephalexin taken four times daily.¹¹

In children, the numbers look even slightly better. A pediatric trial found clinical cure rates of about 98% for cefdinir versus 94% for cephalexin, with near-perfect microbiologic eradication in both groups.¹² The main bacteria causing these infections were Staphylococcus aureus and Streptococcus pyogenes, both of which cefdinir handles well. One thing to note is that while the adult study found similar cure rates for both methicillin-susceptible and methicillin-resistant Staph aureus (MRSA), cefdinir is not considered a reliable treatment for MRSA infections. The in vitro data and clinical guidelines generally point away from using any oral cephalosporin as a targeted MRSA treatment.

The Red Stool Surprise

If you’ve been prescribed cefdinir and also take iron supplements, give iron-fortified formula to your baby, or eat iron-fortified cereal, there is a well-known but alarming side effect nobody warns you about until it happens: bright red or rust-colored stool. This is not blood. When cefdinir or one of its breakdown products encounters iron in the gut, it forms a reddish complex that passes through harmlessly.¹³ Parents and caregivers understandably panic, and emergency rooms see a steady trickle of worried visits over what is ultimately a cosmetic effect on diaper contents.

The iron interaction also has a pharmacologic side. Iron-containing products can reduce cefdinir absorption, potentially lowering the drug’s effectiveness. Standard advice is to separate the doses: take cefdinir at least two hours before or after iron supplements, antacids containing aluminum or magnesium, or iron-fortified foods when possible. For infants on iron-fortified formula around the clock, this separation can be impractical, and your pediatrician may adjust the approach accordingly.

Risk of C. Difficile Infection

Every antibiotic carries some risk of disrupting gut bacteria enough to allow Clostridioides difficile to take hold, causing diarrhea that ranges from mild to life-threatening. Cefdinir carries a higher-than-average risk in this regard. A large U.S. study covering 2008 through 2020 found that cefdinir was among the antibiotics conferring the highest risk for community-acquired C. difficile infection, second only to clindamycin.¹⁴ Separate hospital-based data similarly identified oral cephalosporins as a high-risk category for C. difficile.¹⁵

This does not mean cefdinir should be feared. C. difficile infection remains uncommon in otherwise healthy people, and the absolute risk from any single antibiotic course is small. But the relative risk matters for certain groups: older adults, people who have had C. difficile before, people in nursing homes, and anyone who has been on multiple courses of antibiotics recently. For those individuals, a prescriber might reasonably choose a lower-risk antibiotic when one is available.

Cefdinir and Penicillin Allergy

A common clinical question is whether someone allergic to penicillin can safely take cefdinir. The older teaching that anyone with a penicillin allergy should avoid all cephalosporins has been largely debunked. The cross-reactivity between penicillins and cephalosporins depends heavily on which generation of cephalosporin is involved. A meta-analysis found that first-generation cephalosporins showed a significantly increased risk of allergic reactions in penicillin-allergic patients, but second-generation and third-generation cephalosporins did not.¹⁶ Cefdinir is a third-generation cephalosporin, placing it in the lower-risk category.

That said, if your penicillin allergy involved a severe reaction like anaphylaxis, swelling of the throat, or widespread hives, most providers will still exercise caution. The decision usually depends on how confident the allergy history is and how severe the original reaction was. Penicillin allergy testing, which can confirm or rule out a true allergy in most people, has become more accessible in recent years and can simplify the decision considerably.

Why Kids Tend to Take It Without a Fight

Anyone who has tried to get a four-year-old to swallow a bitter antibiotic suspension knows that taste can make or break a treatment course. Cefdinir scores well on palatability. In a pooled analysis of seven randomized crossover studies, about 83% of children aged four to eight rated cefdinir’s taste as “really good” or “good,” compared with roughly 74% who gave the same ratings to comparator antibiotics including amoxicillin-clavulanate, cefprozil, azithromycin, and generic amoxicillin.¹⁷ An earlier trial found an even wider gap, with 85% rating cefdinir’s taste favorably versus 63% for the comparators.¹⁸

This is not trivial. An antibiotic that a child spits out or refuses after day two is an antibiotic that does not work. Incomplete courses contribute to treatment failure and bacterial resistance. The combination of a short treatment course (five days for many indications) and a palatable suspension gives cefdinir a genuine compliance advantage in pediatric care.

What Cefdinir Does Not Cover

Knowing what an antibiotic cannot do is as important as knowing its uses. Cefdinir has no meaningful activity against MRSA in clinical practice, despite some trial data showing equivalent outcomes for small numbers of MRSA skin infections. It does not cover Pseudomonas aeruginosa, a common cause of serious infections in hospitalized patients. It is not useful for urinary tract infections caused by Enterococcus species. And it has no activity against atypical respiratory pathogens like Mycoplasma pneumoniae or Chlamydophila pneumoniae, which cause “walking pneumonia” and other atypical presentations.

Against its core targets, though, susceptibility remains high. Testing of isolates from North American skin infections found that cefdinir retained full activity against methicillin-susceptible staphylococci and beta-hemolytic streptococci, with high susceptibility rates against E. coli and Klebsiella pneumoniae as well.¹⁹

Dosing Adjustments for Kidney Problems

Cefdinir is cleared from the body primarily through the kidneys, with a half-life of roughly 1.5 hours in people with normal kidney function. In children, the drug behaves similarly to adults when dosed on a per-body-surface-area basis.²⁰ But in people with significant kidney impairment, the drug hangs around much longer. A pharmacokinetic study in hemodialysis patients found that the elimination half-life stretched to about 17 hours, over ten times the normal value. Hemodialysis itself removed roughly 61% of the drug from the blood, so patients on dialysis typically need a reduced dose timed around their dialysis sessions.²¹ If you have kidney disease and are prescribed cefdinir, your dose will almost certainly be adjusted downward. This is standard practice and not a reason for concern, just something to confirm with your pharmacist.

The Stewardship Question

There is a growing conversation in infectious disease circles about whether cefdinir is prescribed more often than it should be. The concern isn’t that the drug doesn’t work; it clearly does across its approved indications. The issue is that for many common infections, narrower-spectrum antibiotics like amoxicillin or penicillin work just as well and do less collateral damage to gut flora. A broader-spectrum drug like cefdinir disrupts a wider swath of normal bacteria, which increases the risk of complications like C. difficile and contributes to the broader problem of antibiotic resistance.

Cefdinir’s convenience factors, once-daily dosing, good taste, and short courses, have made it popular among prescribers, sometimes in situations where a simpler antibiotic would suffice. Guidelines from major infectious disease organizations generally position cefdinir as a second-line agent: the drug you reach for when penicillin or amoxicillin fails, isn’t tolerated, or doesn’t cover the likely pathogen. When it’s used in that role, it earns its place. Where the debate gets sharper is when it becomes the default first choice for a straightforward ear infection or sore throat that amoxicillin would handle just fine. No single prescription is going to tip the balance of global antibiotic resistance, but patterns of overprescription add up, and cefdinir’s broad spectrum makes it a case study in the tradeoff between convenience and stewardship.